Canna Clinical Trials Archives - Weed World Magazine

Cannabis and the Anxiety of Fragmentation-A Systems Approach for Finding an Anxiolytic Cannabis Chemotype

Canna Clinical TrialsBy WW 15th November 2018 Leave a comment

Cannabis sativa is a medicinal herb with a diverse range of chemotypes that can exert both anxiolytic and anxiogenic effects on humans. Medical cannabis patients receiving organically grown cannabis from a single source were surveyed about the effectiveness of cannabis for treating anxiety. Patients rated cannabis as highly effective overall for treating anxiety with an average score of 8.03 on a Likert scale of 0 to 10 (0 = not effective, 10 = extremely effective).

Medical Cannabis: A plurimillennial history of an evergreen

Canna Clinical TrialsBy WW 14th November 2018 Leave a comment

The history of Cannabis goes along that of humankind, as speculated based on geographical and evolutionary models together with historic data collected to date. We report through the centuries evidence of its use in numerous pathologic conditions especially for its anti-inflammatory, antiseptic, and anticonvulsing properties that support the requirement to direct our present research efforts into the definitive understanding of its efficacy.

Effect of adding medical cannabis to analgesic treatment in patients with low back pain related to fibromyalgia: an observational cross-over single centre study

Canna Clinical TrialsBy WW 13th November 2018 Leave a comment

Low back pain (LBP) occurs in many patients with fibromyalgia (FM). The current study aimed to assess the possible pain and function amelioration associated with medical cannabis therapy (MCT) in this setting.
This observational cross-over study demonstrates an advantage of MCT in FM patients with LBP as compared with Standard Analgesic Treatment. Further randomised clinical trial studies should assess whether these results can be generalised to the FM population at large.

A Review of the Therapeutic Antitumor Potential of Cannabinoids

Canna Clinical TrialsBy WW 12th November 2018 Leave a comment

The aim of this review is to discuss cannabinoids from a preclinical and clinical oncological perspective and provide the audience with a concise, retrospective overview of the most significant findings concerning the potential use of cannabinoids in cancer treatment. Further studies require extensive monitoring of the effects of cannabinoids alone or in combination with standard anticancer strategies. With such knowledge, cannabinoids could become a therapy of choice in contemporary oncology.

Nabiximols in the treatment of spasticity, pain and urinary symptoms due to multiple sclerosis

Canna Clinical TrialsBy WW 11th November 2018 Leave a comment

Over the last two decades, experimental and clinical data suggest a therapeutic benefit of cannabis-based medicines for a variety of multiple sclerosis (MS) symptoms. Clinical trials, both with synthetic or plant-derived cannabinoids, have demonstrated clinical efficacy of cannabinoids for the treatment of spasticity, neuropathic pain and bladder dysfunction.

[From cannabis to selective CB2R agonists: molecules with numerous therapeutical virtues].

Canna Clinical TrialsBy WW 10th November 2018 Leave a comment

Originally used in Asia for the treatment of pain, spasms, nausea and insomnia, marijuana is the most consumed psychotropic drug worldwide. The interest of medical cannabis has been reconsidered recently, leading to many scientific researches and commercialization of these drugs.

What place for ▾ cannabis extract in MS?

Canna Clinical TrialsBy WW 9th November 2018 Leave a comment

Multiple sclerosis (MS) is a neurological condition that is estimated to affect around 60,000 people in England and Wales, with a lifetime risk in the UK of 1 in 1,000.(1,2) Spasticity (an increase in muscle tone) is a common symptom of MS, resulting in muscle spasms, immobility, disturbed sleep and pain.

A user’s guide to cannabinoid therapies in oncology

Canna Clinical TrialsBy WW 8th November 2018 Leave a comment

“Cannabinoid” is the collective term for a group of chemical compounds that either are derived from the Cannabis plant, are synthetic analogues, or occur endogenously. Although cannabinoids interact mostly at the level of the currently recognized cannabinoid receptors, they might have cross reactivity, such as at opioid receptors. The use of cannabinoid therapies could be effective in improving quality of life and possibly modifying malignancy by virtue of direct effects and in improving compliance or adherence with disease-modulating treatments such as chemotherapy and radiation therapy.

The Pharmacological Basis of Cannabis Therapy for Epilepsy

Canna Clinical TrialsBy WW 7th November 2018 Leave a comment

Recently, cannabis has been suggested as a potential alternative therapy for refractory epilepsy, which affects 30% of epilepsy, both adults and children, who do not respond to current medications. There is a large unmet medical need for new antiepileptics that would not interfere with normal function in patients with refractory epilepsy and conditions associated with refractory seizures.

Cannabinoids and Epilepsy

Canna Clinical TrialsBy WW 6th November 2018 Leave a comment

Cannabis has been used for centuries to treat seizures. Recent anecdotal reports, accumulating animal model data, and mechanistic insights have raised interest in cannabis-based antiepileptic therapies. These studies suggest that CBD avoids the psychoactive effects of the endocannabinoid system to provide a well-tolerated, promising therapeutic for the treatment of seizures, while whole-plant cannabis can both contribute to and reduce seizures.

Category Archives: Canna Clinical Trials